VKTXViking Therapeutics, Inc.

They are fairly risky, but their potential upside is massive.

It's not much of a rivalry yet.

In a slow news month for the company, investors focused on the cost of its phase 3 trials rather than their benefits.

Why Viking Therapeutics' VK2735 News Matters For Investors Viking Therapeutics (VKTX) has drawn fresh attention after commentary on its VK2735 drug candidate highlighted the potential appeal of less frequent injections and the possibility of use in combination maintenance therapy for weight loss and metabolic disorders. See our latest analysis for Viking Therapeutics. For context, Viking Therapeutics' share price is US$32.61 after a 1 day share price return of 2.74%. However, the 30 day share...

In late July 2026, Viking Therapeutics reported Q2 and first-half net losses of US$128.02 million and US$286.35 million respectively, while also filing a US$500 million at-the-market equity offering and an omnibus shelf registration covering multiple securities types. Despite these wider losses and fresh financing capacity, attention has increasingly centered on obesity candidate VK2735, whose potential for less frequent dosing and combination use has drawn industry interest and helped frame...

Viking Therapeutics (VKTX) could unlock substantial additional opportunities for VK2735 through less

There are other reasons to pay attention to Viking Therapeutics.

Viking Therapeutics said the proceeds would be used to support the continued development and commercialization of its lead obesity drug VK2735.

Viking Therapeutics beats second-quarter loss estimates as it advances late-stage obesity studies despite sharply higher R&D spending tied to its expanding pipeline.

Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.

Viking Therapeutics Inc (VKTX) reports a net loss of $128.1 million for Q2 2026, driven by increased R&D spending, while key Phase III programs for VK2735 remain on track.

Viking Therapeutics (NASDAQ:VKTX) reported a wider second-quarter loss as the company increased spending to advance its obesity pipeline, including its lead dual GLP-1/GIP receptor agonist, VK2735, through Phase III development in injectable and planned oral formulations. The company reported a net

Viking has no approved drug products, and in the pre-revenue phase, investor attention centers almost entirely on clinical progress.

FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.

The stock looks like a high-risk, high-reward play.

According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Viking Therapeutics stock has delivered a very large 5 year return, yet its current valuation checks lean expensive, setting up a clear tension between strong past gains and what the current price implies about future expectations. Viking Therapeutics has returned roughly 4.8x over the past 5 years, which means a lot of optimism is already embedded in the share price. Excitement around new diabetes and metabolic therapies can support high expectations, but execution risk in advancing and...

Viking Therapeutics (NasdaqCM:VKTX) has appointed Dorothy Gemmell to its Board of Directors. Gemmell brings extensive experience in healthcare commercialization and leadership at large healthcare organizations. Viking Therapeutics, trading at $35.39, has drawn attention with the appointment of Dorothy Gemmell to its board, adding a leader with deep commercialization experience to its governance mix. The stock has delivered very large gains over the past 5 years and is up 158.1% over 3...

Viking Therapeutics, Inc. (VKTX) reached $35.39 at the closing of the latest trading day, reflecting a -5.15% change compared to its last close.

Viking's latest program seeks to push the envelope in weight loss efficacy.

Wall Street analysts are highly bullish on Viking Therapeutics, not least because of its promising weight-loss drug, with ongoing and upcoming phase 3 trials.

The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $37.08, representing a +1.95% change from its previous close.

VKTX's Q2 report could hinge on VK2735 pipeline updates as investors await progress on obesity studies and maintenance dosing plans.

The weight-loss boom has created one of the market's biggest opportunities — and some of its most punishing failures.

Viking Therapeutics, Inc. (VKTX) reached $36.37 at the closing of the latest trading day, reflecting a -3.81% change compared to its last close.

Investors need to ask tough questions before initiating a position in this biotech company.

Viking Therapeutics Inc. (NASDAQ:VKTX) is one of the 10 affordable biotech stocks to buy right now. On June 24, Viking Therapeutics Inc. (NASDAQ:VKTX) disclosed the launch of a Phase 1 Single Ascending Dose (SAD) medical study of VK3019. VK3019 is an experimental Dual Amylin and Calcitonin Receptor Agonist (DACRA), being developed as a possible weight […]